Sigilon Therapeutics, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Sigilon Therapeutics, Inc. | SGTX - NASDAQ |
$17.00-$19.00 | $18.00 | $22.00 | 7 million | 12/4/2020 |
| Morgan Stanley, Jefferies, Barclays, Canaccord Genuity | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2020-11-13 Terms Added 2020-11-30 | ||||||
Sigilon Therapeutics, Inc. Quote & Chart - Click for current quote - SGTX
IPO Boutique aggregates information on public companies and private companies, such as "SGTX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Sigilon Therapeutics, Inc. (adapted from Sigilon Therapeutics, Inc. prospectus):
They are a clinical-stage biotechnology company pioneering a new class of therapeutics and seeking to develop functional cures for patients with chronic diseases by providing stable and durable levels of therapeutic molecules to patients.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage biotechnology company pioneering a new class of therapeutics and seeking to develop functional cures for patients with chronic diseases by providing stable and durable levels of therapeutic molecules to patients.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "SGTX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.